Latest news with #EledonPharmaceuticals
Yahoo
5 days ago
- Business
- Yahoo
Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ('Eledon') (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress (WTC) taking place in San Francisco from August 2-6, 2025. The oral presentation will feature updated results from approximately 30 kidney transplant recipients and will be presented by Dr. John Gill from the University of British Columbia. Details of the oral presentation are as follows: Title: Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b StudySession: Oral Presentation, Kidney Novel Immunosuppressant StrategiesPresenter: John Gill, MD, MS, University of British Columbia, Vancouver, CanadaSession Date and Time: Wednesday, August 6, 2025: 10:00 a.m. – 11:15 a.m. PT Following the session, a copy of the presentation can be found on the Investor section of the Company's website at The Company will also sponsor a satellite symposium at WTC titled: 'What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?', to be held on Sunday, August 3, at 1:00 pm PT. Faculty include Allan Kirk, MD, Duke University School of Medicine, Oriol Bestard, MD, PhD, MD, Vall d'Hebron University Hospital, John Gill, MD, MS, University of British Columbia, Alexandre Loupy, MD, PhD, Necker Hospital and Deirdre Sawinski, MD, Weill Cornell Medical College. In addition to the oral presentation, new preclinical data, utilizing tegoprubart for the prevention of rejection in non-human primates undergoing liver transplantation, will be presented by Dr. Andrew Adams in a poster session: Title: Anti-CD154 Facilitates Long-Term Liver Allograft Survival in Non-Human PrimatesSession: Poster PresentationPresenter: Andrew Adams, MD, PhD, University of MinnesotaDate and Time: Sunday, August 3, 2025, 3:30 p.m. PT About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company's website at Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Investor Contact: Stephen JasperGilmartin Group(858) 525 2047stephen@ Media Contact: Jenna UrbanCG Life(212) 253 8881jurban@ Source: Eledon Pharmaceuticals
Yahoo
14-07-2025
- Business
- Yahoo
New Strong Buy Stocks for July 14th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Wipro Limited WIT: This information technology, consulting, and business process services company has seen the Zacks Consensus Estimate for its current year earnings increasing 7.1% over the last 60 days. Wipro Limited price-consensus-chart | Wipro Limited Quote KNOT Offshore Partners LP KNOP: This operator of shuttle tankers has seen the Zacks Consensus Estimate for its current year earnings increasing 44.9% over the last 60 days. KNOT Offshore Partners LP price-consensus-chart | KNOT Offshore Partners LP Quote Penguin Solutions, Inc. PENG: This designer and developer of enterprise solutions has seen the Zacks Consensus Estimate for its current year earnings increasing 14.2% over the last 60 days. Penguin Solutions, Inc. price-consensus-chart | Penguin Solutions, Inc. Quote Eledon Pharmaceuticals, Inc. ELDN: This clinical stage biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 23.8% over the last 60 days. Eledon Pharmaceuticals, Inc. price-consensus-chart | Eledon Pharmaceuticals, Inc. Quote KDDI Corporation KDDIY: This Japanese telecommunications services company has seen the Zacks Consensus Estimate for its current year earnings increasing 39.7% over the last 60 days. KDDI Corporation Unsponsored ADR price-consensus-chart | KDDI Corporation Unsponsored ADR Quote You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Wipro Limited (WIT) : Free Stock Analysis Report KDDI Corporation Unsponsored ADR (KDDIY) : Free Stock Analysis Report KNOT Offshore Partners LP (KNOP) : Free Stock Analysis Report Eledon Pharmaceuticals, Inc. (ELDN) : Free Stock Analysis Report Penguin Solutions, Inc. (PENG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
Investors might want to bet on Eledon Pharmaceuticals, Inc. (ELDN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for Eledon Pharmaceuticals basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock. Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Eledon Pharmaceuticals imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher. As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>. This company is expected to earn -$0.92 per share for the fiscal year ending December 2025, which represents a year-over-year change of -9100%. Analysts have been steadily raising their estimates for Eledon Pharmaceuticals. Over the past three months, the Zacks Consensus Estimate for the company has increased 8.4%. Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of Eledon Pharmaceuticals to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eledon Pharmaceuticals, Inc. (ELDN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
22-03-2025
- Business
- Yahoo
We're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Given this risk, we thought we'd take a look at whether Eledon Pharmaceuticals (NASDAQ:ELDN) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. A company's cash runway is calculated by dividing its cash hoard by its cash burn. In December 2024, Eledon Pharmaceuticals had US$140m in cash, and was debt-free. In the last year, its cash burn was US$47m. So it had a cash runway of about 3.0 years from December 2024. Arguably, that's a prudent and sensible length of runway to have. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Eledon Pharmaceuticals Because Eledon Pharmaceuticals isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With the cash burn rate up 20% in the last year, it seems that the company is ratcheting up investment in the business over time. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years. While Eledon Pharmaceuticals does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Eledon Pharmaceuticals' cash burn of US$47m is about 23% of its US$206m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution. On this analysis of Eledon Pharmaceuticals' cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. Separately, we looked at different risks affecting the company and spotted 4 warning signs for Eledon Pharmaceuticals (of which 3 make us uncomfortable!) you should know about. Of course Eledon Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
04-03-2025
- Business
- Yahoo
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ('Eledon') (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company's website at Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Investor Contact: Stephen JasperGilmartin Group(858) 525 2047stephen@ Media Contact: Jenna UrbanCG Life(212) 253 8881jurban@ Source: Eledon Pharmaceuticals
